Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 7/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 5/20 | 0.89 |
| ▸ | CES1 | P23141 | 1/20 | 0.71 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.70 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.70 |
| ▸ | AHR | P35869 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496401 | 1.00 | GRM4 (1.00) | GRM4HDAC6KDRCES1KCNK3 | |
| SCHEMBL7990375 | 0.90 | KDR (0.84) | GRM4HDAC6KDRKCNK3KCNK9 | |
| SCHEMBL29217373 | 0.87 | GRM4 (0.77) | GRM4HDAC6KDRKCNK3KCNK9 | |
| SCHEMBL28871718 | 0.86 | GRM4 (0.76) | GRM4HDAC6KDRCES1KCNK3 | |
| SCHEMBL27181366 | 0.86 | GRM4 (0.74) | GRM4HDAC6KDRCES1KCNK3 | |
| SCHEMBL30926458 | 0.86 | GRM4 (0.74) | GRM4HDAC6KDRCES1KCNK3 | |
| SCHEMBL4731965 | 0.85 | GRM4 (0.74) | GRM4HDAC6KDRAHRNPC1 | |
| SCHEMBL2528081 | 0.84 | GRM4 (0.72) | GRM4HDAC6KDRKCNK3KCNK9 | |
| SCHEMBL30926765 | 0.83 | GRM4 (0.77) | GRM4HDAC6KDRNPC1RAB9A | |
| SCHEMBL27180433 | 0.83 | GRM4 (0.77) | GRM4HDAC6KDRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE | 2011-10-20 | — | — | US | claimed |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-03 | — | — | US | claimed |
| US-20220118117-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4 | MASSACHUSETTS GEN HOSPITAL (US) | 2022-04-21 | — | — | US | disclosed |
| CN-112047879-B | Method for selectively synthesizing halogenated arylamine by copper catalysis | 浙江工业大学 | 2022-01-14 | — | — | CN | disclosed |
| CN-112047879-A | Method for selectively synthesizing halogenated arylamine by copper catalysis | 浙江工业大学 | 2020-12-08 | — | — | CN | disclosed |
| US-8524726-B2 | Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20130137704-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma, SA (CH) | 2013-05-30 | — | — | US | disclosed |
| US-20130131092-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma, SA (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE | 2011-10-20 | — | — | US | disclosed |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137704-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | GRM4 1/4885HDAC6 2600/4885KDR 4100/4885 |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | GRM4 1/4885HDAC6 2600/4885KDR 4100/4885 |
| US-20220118117-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4 | GRM2, GRM4, GRM1 | GRM4 2/4885HDAC6 2334/4885KDR 2713/4885 |
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | GRM4, GRM1, GRM3 | GRM4 1/4885HDAC6 2600/4885KDR 4100/4885 |
| US-20130131092-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | GRM4 1/4885HDAC6 2600/4885KDR 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.